Hyperglycemia is common in deceased donors, and provokes numerous adverse events in hepatocytic mitochondria.
Objective
To determine whether hyperglycemia in deceased donors is associated with graft dysfunction after orthotopic liver transplant.
Methods
Charts on 572 liver transplants performed at the Cleveland Clinic between January 2005 and October 2010 were reviewed. The primary measure was time-weighted averages of donors' glucose measurements. Liver graft dysfunction was defined as (1) primary nonfunction as indicated by death or retransplant or (2) liver graft dysfunction as indicated by an aspartate amino transferase level greater than 2000 U/L or prothrombin time greater than 16 seconds during the first postoperative week. The relationship of interest was estimated by using a multivariable logistic regression.
Results
The incidence of graft dysfunction was 25%. No significant relationship was found between the range of donor glucose measurements and liver graft dysfunction after donor characteristics were adjusted for (P = .14, Wald test, adjusted odds ratio [95% CI] for liver graft dysfunction corresponding to a relative doubling in time-weighted average for donor glucose of 1.43 [0.89–2.30]). The results thus do not suggest that strict glucose control in donors is likely to improve graft quality.
Get full access to this article
View all access options for this article.
References
1.
KutsogiannisDJPagliarelloGDoigCRossHShemieSD. Medical management to optimize donor organ potential: Review of the literature. Can J Anaesth.2006;53(8):820–830.
2.
van Der HoevenJATer HorstGJMolemaG. Effects of brain death and hemodynamic status on function and immunologic activation of the potential donor liver in the rat. Ann Surg.2000;232(6):804–813.
3.
ZaroffJGRosengardBRArmstrongWF. Consensus conference report: Maximizing use of organs recovered from the cadaver donor: Cardiac recommendations, March 28–29, 2001, Crystal City, Va. Circulation.2002;106(7):836–841.
4.
KolkertJL't HartNAvan DijkAOttensPJPloegRJLeuveninkHG. The gradual onset brain death model: A relevant model to study organ donation and its consequences on the outcome after transplantation. Lab Anim.2007;41(3):363–371.
5.
MassonFThicoipeMGinH. The endocrine pancreas in brain-dead donors. A prospective study in 25 patients. Transplantation.1993;56(2):363–367.
6.
NovitzkyDCooperDKRosendaleJDKauffmanHM. Hormonal therapy of the brain-dead organ donor: Experimental and clinical studies. Transplantation.2006;82(11):1396–1401.
7.
Van den BergheGWoutersPJBouillonR. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med.2003;31(2):359–366.
8.
VanhorebeekILangoucheL. Molecular mechanisms behind clinical benefits of intensive insulin therapy during critical illness: Glucose versus insulin. Best Pract Res Clin Anaesthesiol.2009;23(4):449–459.
9.
MassionPBMoniotteSBalligandJL. Nitric oxide: Does it play a role in the heart of the critically ill?Curr Opin Crit Care.2001;7(5):323–336.
10.
RassiasAJMarrinCAArrudaJWhalenPKBeachMYeagerMP. Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg.1999;88(5):1011–1016.
11.
RassiasAJGivanALMarrinCAWhalenKPahlJYeagerMP. Insulin increases neutrophil count and phagocytic capacity after cardiac surgery. Anesth Analg.2002;94(5):1113–1119.
12.
LingPRSmithRJBistrianBR. Hyperglycemia enhances the cytokine production and oxidative responses to a low but not high dose of endotoxin in rats. Crit Care Med.2005;33(5):1084–1089.
13.
LingPRMuellerCSmithRJBistrianBR. Hyperglycemia induced by glucose infusion causes hepatic oxidative stress and systemic inflammation, but not STAT3 or MAP kinase activation in liver in rats. Metabolism.2003;52(7):868–874.
14.
LefebvrePJScheenAJ. The postprandial state and risk of cardiovascular disease. Diabet Med.1998;15(suppl 4):S63–68.
15.
van den BergheGWoutersPWeekersF. Intensive insulin therapy in the critically ill patients. N Engl J Med.2001;345(19):1359–1367.
16.
EllgerBDebaveyeYVanhorebeekI. Survival benefits of intensive insulin therapy in critical illness: Impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes.2006;55(4):1096–1105.
17.
VanhorebeekILangoucheLVan den BergheG. Glycemic and nonglycemic effects of insulin: How do they contribute to a better outcome of critical illness?Curr Opin Crit Care.2005;11(4):304–311.
18.
NICE-SUGAR Study Investigators, FinferSChittockDRSuSY. Intensive versus conventional glucose control in critically ill patients. N Engl J Med.2009;360(13):1283–1297.
19.
MonnierLMasEGinetC. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA.2006;295(14):1681–1687.
20.
EgiMBellomoRReadeMC. Is reducing variability of blood glucose the real but hidden target of intensive insulin therapy?Crit Care.2009;13(2):302.
21.
EgiMBellomoRStachowskiEFrenchCJHartG. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology.2006;105(2):244–252.
22.
Blasi-IbanezAHiroseRFeinerJ. Predictors associated with terminal renal function in deceased organ donors in the intensive care unit. Anesthesiology.2009;110(2):333–341.
23.
PloegRJD'AlessandroAMKnechtleSJ. Risk factors for primary dysfunction after liver transplantation—a multivariate analysis. Transplantation.1993;55(4):807–813.
24.
AkaikeH. A new look at the statistical model identification. IEEE T Automat Contr.1974;19(6):716–723.
25.
DeLongERDeLongDMClarke-PearsonDL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics.1988;44(3):837–845.
KoenkerRHallockKF. Quantile regression: An introduction. J Econ Perspect.2001;15(4):143–156.
28.
PoirierDJ. Piecewise regression using cubic splines. J Am Stat Assoc.1973;68(343):515–524.
29.
RullRVidalOMomblanD. Evaluation of potential liver donors: Limits imposed by donor variables in liver transplantation. Liver Transpl.2003;9(4):389–393.
30.
PokornyHLangerFHerknerH. Influence of cumulative number of marginal donor criteria on primary organ dysfunction in liver recipients. Clin Transplant.2005;19(4):532–536.
31.
CuendeNMirandaBCanonJFGarridoGMatesanzR. Donor characteristics associated with liver graft survival. Transplantation.2005;79(10):1445–1452.
32.
FengSGoodrichNPBragg-GreshamJL. Characteristics associated with liver graft failure: The concept of a donor risk index. Am J Transplant.2006;6(4):783–790.
33.
AmmoriJBSigakisMEnglesbeMJO'ReillyMPelletierSJ. Effect of intraoperative hyperglycemia during liver transplantation. J Surg Res.2007;140(2):227–233.
34.
MaringJKKlompmakerIJZwavelingJHKranenburgKTen VergertEMSlooffMJ. Poor initial graft function after orthotopic liver transplantation: Can it be predicted and does it affect outcome? An analysis of 125 adult primary transplantations. Clin Transplant.1997;11(5 pt 1):373–379.
